Profile data is unavailable for this security.
About the company
Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
- Revenue in USD (TTM)3.55bn
- Net income in USD631.70m
- Incorporated1984
- Employees27.05k
- LocationDr Reddy's Laboratories Ltd8-2-337, Road No.3 Banjara HillsHYDERABAD 500034IndiaIND
- Phone+91 4 049002900
- Fax+91 4 049002999
- Websitehttps://www.drreddys.com/
More ▼
Mergers & acquisitions
| Acquired company | DRREDDY:NSI since announced | Transaction value |
|---|---|---|
| Menolabs LLC | 5.11% | 3.00m |
Data delayed at least 15 minutes, as of Nov 25 2024 04:01 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Corcept Therapeutics Incorporated | 628.56m | 141.82m | 6.03bn | 352.00 | 45.32 | 9.40 | 42.17 | 9.59 | 1.27 | 1.27 | 5.64 | 6.12 | 0.9121 | 1.26 | 13.32 | 1,785,668.00 | 20.58 | 21.17 | 25.10 | 23.85 | 98.44 | 98.52 | 22.56 | 27.23 | 3.64 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
| Halozyme Therapeutics, Inc. | 947.36m | 392.47m | 6.23bn | 373.00 | 16.22 | 13.77 | 13.15 | 6.58 | 3.02 | 3.02 | 7.30 | 3.56 | 0.4724 | 1.30 | 3.77 | 2,539,826.00 | 19.57 | 18.22 | 20.73 | 21.97 | 82.09 | 79.05 | 41.43 | 39.36 | 9.15 | -- | 0.7687 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| Elanco Animal Health Inc | 4.45bn | 205.00m | 6.60bn | 9.30k | 32.69 | 1.01 | 7.56 | 1.48 | 0.4087 | 0.4087 | 8.99 | 13.20 | 0.3224 | 1.21 | 5.09 | 478,924.70 | 1.48 | -3.27 | 1.64 | -3.65 | 54.69 | 54.28 | 4.60 | -11.53 | 1.31 | 0.9883 | 0.4005 | -- | 0.136 | 7.57 | -1,478.21 | -- | 2.74 | -- |
| Jazz Pharmaceuticals PLC | 3.99bn | 463.16m | 7.66bn | 2.80k | 17.84 | 1.84 | 6.86 | 1.92 | 7.10 | 7.10 | 60.27 | 69.01 | 0.3404 | 0.7371 | 5.91 | 1,425,969.00 | 3.97 | 1.48 | 4.46 | 1.62 | 89.37 | 88.79 | 11.65 | 4.26 | 3.74 | 2.82 | 0.5944 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
| Intra-Cellular Therapies Inc | 613.73m | -86.37m | 9.08bn | 610.00 | -- | 7.93 | -- | 14.80 | -0.8595 | -0.8595 | 6.10 | 10.80 | 0.6011 | 1.42 | 4.94 | 1,006,112.00 | -8.46 | -38.27 | -9.74 | -42.77 | 92.30 | -- | -14.07 | -128.42 | 7.51 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
| Roivant Sciences Ltd | 78.54m | 4.76bn | 9.12bn | 845.00 | 2.24 | 1.78 | 1.96 | 116.14 | 5.60 | 5.66 | 0.1007 | 7.03 | 0.019 | -- | 2.91 | 92,940.83 | 111.75 | -- | 139.09 | -- | 89.14 | -- | 5,884.92 | -- | -- | -- | 0.00 | -- | 103.65 | -- | 487.06 | -- | -- | -- |
| Catalent Inc | 4.42bn | -413.00m | 11.07bn | 16.90k | -- | 3.12 | 143.75 | 2.50 | -2.27 | -2.27 | 24.33 | 19.57 | 0.4482 | 4.92 | 3.27 | 261,656.80 | -4.19 | 0.0124 | -4.80 | 0.014 | 21.82 | 28.93 | -9.34 | 0.0278 | 1.93 | 0.7814 | 0.5821 | -- | 2.77 | 11.71 | -307.42 | -- | 8.44 | -- |
| Dr Reddy's Laboratories Ltd (ADR) | 3.55bn | 631.70m | 11.97bn | 27.05k | 18.74 | 3.27 | 14.55 | 3.37 | 0.7577 | 0.7577 | 4.26 | 4.34 | 0.7377 | 1.85 | 3.89 | 131,315.90 | 13.33 | 11.35 | 18.20 | 16.03 | 59.29 | 55.62 | 18.07 | 14.59 | 1.34 | -- | 0.1357 | 16.54 | 13.54 | 12.66 | 23.56 | 24.26 | 18.72 | 14.77 |
| Biomarin Pharmaceutical Inc | 2.75bn | 322.29m | 12.25bn | 3.40k | 38.65 | 2.26 | 29.02 | 4.45 | 1.66 | 1.66 | 14.02 | 28.41 | 0.4046 | 0.5242 | 4.08 | 809,411.60 | 4.74 | 0.7116 | 5.49 | 0.8079 | 78.95 | 76.30 | 11.71 | 2.05 | 2.62 | -- | 0.099 | 0.00 | 15.42 | 10.16 | 36.51 | -- | -5.74 | -- |
| Incyte Corp | 4.08bn | 32.48m | 13.82bn | 2.52k | 512.47 | 4.36 | 114.42 | 3.39 | 0.14 | 0.14 | 18.79 | 16.45 | 0.715 | 4.23 | 5.76 | 1,614,842.00 | 0.5698 | 9.07 | 0.7404 | 11.02 | 93.37 | 94.97 | 0.7969 | 13.68 | 1.82 | -- | 0.01 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
| Royalty Pharma plc | 2.27bn | 1.15bn | 15.57bn | 89.00 | 10.33 | 2.27 | 21.70 | 6.87 | 2.56 | 2.56 | 3.80 | 11.63 | 0.1337 | -- | 72.15 | 25,460,710.00 | 10.11 | 9.57 | 13.30 | 12.42 | -- | -- | 75.64 | 67.80 | -- | -- | 0.4258 | 23.47 | 5.24 | 5.58 | 2,549.50 | -3.80 | 50.99 | -- |
| Viatris Inc | 15.05bn | -883.30m | 15.96bn | 38.00k | -- | 0.8063 | 8.36 | 1.06 | -0.7389 | -0.7389 | 12.54 | 16.58 | 0.3219 | 2.23 | 4.94 | 396,013.20 | -1.89 | 0.0887 | -2.23 | 0.1061 | 42.49 | 40.29 | -5.87 | 0.2891 | 0.9615 | 2.37 | 0.443 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
Data as of Nov 22 2024. Currency figures normalised to Dr Reddy's Laboratories Ltd's reporting currency: US Dollar USD
1.59%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Robeco Institutional Asset Management BVas of 30 Sep 2024 | 2.07m | 0.25% |
| RBC Global Asset Management (UK) Ltd.as of 30 Sep 2024 | 1.99m | 0.24% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 1.95m | 0.23% |
| Aperio Group LLCas of 30 Sep 2024 | 1.61m | 0.19% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 1.11m | 0.13% |
| Aikya Investment Management Ltd.as of 30 Sep 2024 | 1.09m | 0.13% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 944.40k | 0.11% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 909.91k | 0.11% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 859.66k | 0.10% |
| Parametric Portfolio Associates LLCas of 30 Sep 2024 | 742.74k | 0.09% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
